Compare ONON & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONON | IMVT |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 8.5B |
| IPO Year | 2021 | 2019 |
| Metric | ONON | IMVT |
|---|---|---|
| Price | $28.05 | $39.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 8 |
| Target Price | ★ $60.15 | $33.00 |
| AVG Volume (30 Days) | ★ 9.1M | 1.1M |
| Earning Date | 05-12-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.58 | N/A |
| Revenue Next Year | $19.98 | N/A |
| P/E Ratio | $56.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.56 | $14.58 |
| 52 Week High | $51.08 | $45.42 |
| Indicator | ONON | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 29.90 | 38.14 |
| Support Level | N/A | $37.16 |
| Resistance Level | $39.02 | $41.22 |
| Average True Range (ATR) | 0.80 | 1.52 |
| MACD | -0.10 | -0.68 |
| Stochastic Oscillator | 11.18 | 6.53 |
Founded in Switzerland in 2010, sportswear firm On Holding generates more than 90% of its sales from athletic shoes. The brand is best known for its running shoes and its distinctive CloudTec soles. On also produces athletic apparel (6% of 2025 sales) and accessories (1%). The firm's merchandise is available in more than 80 countries and is sold through both wholesale (58% of sales) and company-owned channels (42%). In 2025, On generated 58% of its sales in North America, 25% in Europe, the Middle East, and Africa, and 17% in the Asia-Pacific region.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.